Tag: Charles Raison

Usona Institute gets FDA breakthrough status for psilocybin in MDD

pharmanewsdaily- November 23, 2019

Wisconsin-based Usona Institute has been granted breakthrough therapy designation for psilocybin from the US Food and Drug Administration (FDA) for the treatment of major depressive ... Read More